

Announcement

Noida (UP), India, Thursday 5th December 2013

Jubilant Life Sciences Limited (JLL) announced today that one of its manufacturing facilities, Jubilant HollisterStier, LLC (JHS) located at Spokane, Washington State, US has been issued a Warning Letter (WL) by US Food and Drug Administration (FDA).

As required by FDA, JHS-Spokane will respond to this WL on or before 12 December 2013. The response will identify corrective actions already been completed as well as some pending corrective actions to ensure on-going cGMP compliance.

FDA specified in the WL that until all corrections have been completed and that they have confirmed correction of the violations and firm compliance to cGMPs, FDA may withhold approval of new applications or supplements listing JHS-Spokane as the drug product manufacturer.

We expect that the on-going manufacturing, distribution and sale of products from this facility will not be impacted as the WL will affect new approvals only. JHS-Spokane is committed to implementing the necessary corrective actions required to address the FDA concerns, and will work closely with the FDA to bring resolution to this matter.

During 1HFY14, the contract manufacturing operations at JHS-Spokane contributed 7% to consolidated sales and 4% to consolidated EBITDA of JLL.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of about 6,300 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 99 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.



For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 4361002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 4361021
E-mail: anupam_jain@jubl.com

Karl Kolah
Citigate Dewe Rogerson
Tel: +91 22 6645 1220
E-mail: karl@cdr-india.com

For Media

Nidhi Malik
Jubilant Life Sciences Limited
Ph: +91-120 4361062
E-mail: nidhi_malik@jubl.com

Sudipta Das
Perfect Relations
Ph: +91 9650602489
E-mail: sdas@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.